Fintel reports that on February 13, 2026, Oppenheimer upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Perform to Outperform. Analyst Price Forecast Suggests 14.51% Upside As of February 4, 2026, the average one-year price target for Vertex Pharmaceuticals is $532.50/Read More
